Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly). Key points: * Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days * Doctors will monitor liver health through blood tests and ultrasound scans * The study will check if Gepaktiv helps improve liver function as effectively as standard treatments. Main measurements: * Changes in liver enzyme levels (ALT, AST) * Reduction in liver size * Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics

NCT Number	NCT07068191
Lead Sponsor	Phenomen Pharma
Conditions	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD), Fatty Liver, Fatty Liver, Alcoholic, Fatty Liver, Nonalcoholic, Fatty Liver Disease
Enrollment	90 participants
Start Date	2025-06-19
Primary Completion	2025-07 (estimated)
Study Completion	2025-08 (estimated)
Updated on ClinicalTrials.gov	2025-07-23